Risedronic Acid
Title: Risedronic Acid
CAS Registry Number: 105462-24-6
CAS Name: [1-Hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid
Additional Names: 2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid
Molecular Formula: C7H11NO7P2
Molecular Weight: 283.11
Percent Composition: C 29.70%, H 3.92%, N 4.95%, O 39.56%, P 21.88%
Literature References: Bisphosphonate antiresorptive agent. Prepn: J. J. Benedict, C. M. Perkins, EP 186405; eidem, US 5583122 (1986, 1996 both to Procter & Gamble). Pharmacology: W. S. S. Jee et al., Bone 14, 493 (1993). Clinical trial in Paget's disease: E. S. Siris et al., J. Bone Miner. Res. 13, 1032 (1998); in postmenopausal bone loss: L. Mortensen et al., J. Clin. Endocrinol. Metab. 83, 396 (1998). Clinical effect on reduction of fracture risk: S. T. Harris et al., J. Am. Med. Assoc. 282, 1344 (1999). Review of pharmacology and clinical efficacy: K. L. Goa, J. A. Balfour, Drugs Aging 13, 83-91 (1998).
 
Derivative Type: Monosodium salt
CAS Registry Number: 115436-72-1
Additional Names: Risedronate sodium
Manufacturers' Codes: NE-58095
Trademarks: Actonel (Procter & Gamble); Optinate (Procter & Gamble)
Molecular Formula: C7H10NNaO7P2
Molecular Weight: 305.09
Percent Composition: C 27.56%, H 3.30%, N 4.59%, Na 7.54%, O 36.71%, P 20.30%
Properties: Fine, white to off-white, odorless crystalline powder. Occurs as the hemi-pentahydrate. Sol in water. Essentially insol in common organic solvents.
 
Therap-Cat: Bone resorption inhibitor.
Keywords: Antiosteoporotic; Antipagetic; Bone Resorption Inhibitor.

Others monographs:
ChlorogeninFenvalerateDFDTAmmonium Salicylate
QuinupramineMatrineStreptonigrinIminodiacetic Acid
SolifenacinRiluzoleSolanAlliin
Sodium Bismuthate(V)Pine TarSulfarsphenamineCeric Sulfate
©2016 DrugLead US FDA&EMEA